UW-Madison School of Pharmacy

Navigation Options

head shot image

Warren E Rose, PharmD, MPH

Associate Professor (CHS)
Associate Professor of Pharmacy and Medicine

 

 

 


Dr. Rose's translational research interests involve the pharmacodynamic effects of antimicrobials on antibacterial resistance development and virulence expression.  His laboratory incorporates multiple in vitro modeling systems to simulate antimicrobial exposures against multi-drug resistant pathogens. These studies are used to evaluate optimal antibiotic activity, antibiotic penetration into simulated infections, the development of antibiotic resistance, and virulence  His clinical studies involve the impact of patient immune responses and bacterial virulence on the treatment outcome of invasive S. aureus infections.

 

Warren Rose joined the University of Wisconsin School of Pharmacy in 2007 as an Assistant Professor (CHS) in the Pharmacy Practice Division.  Prior to arriving at UW, he earned his Pharm.D. from Butler University and then completed a PGY-1 residency in pharmacy practice at Rush University Medical Center in Chicago, IL.  Following residency training, he then completed a post-doctoral fellowship in infectious disease pharmacotherapy at the Anti-Infective Research Laboratory at Wayne State University, Detroit, MI.

 

Education:

  • PharmD  - Butler University
  • Residency - Rush University Medical Center
  • Fellowship - Wayne State University, Anti-infective Research Laboratory
  • MPH - UW Madison

Course Coordinator

  • PHMPRC 656 Pharmacotherapy IV - Infectious Diseases and Oncology Therapeutics 

Lecturer

  • Pharmacology 623
  • Drug Delivery 540
  • Precision Medicine 490
  • Pathways to Pharmacy 

Clerkship Rotation

  • Acute Care Elective 760 - UW Health
  • Clinical Research and Pharmacy Investigation 769

 

Highlighted Publications:

 

Publications 2013-present

  • Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G.  Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum IL-10 concentrations and mortality in patients with bacteremia. Clin Infect Dis. 2017 in press. 
  • Guerra AD, Rose WE, Hematti P, Kao WJ. Minocycline enhances the mesenchymal stromal/stem cell pro-healing phenotype in triple antimicrobial-loaded hydrogels for inoculated cutaneous wound healing. Acta Biomater. 2017 Mar 15;51:184-196.
  • Sakoulas G, Rose W, Berti A, Olson J, Mungia J, Nonejuie P, Sakoulas E, Rybak MJ, Pogliano J, Nizet V. Beta-lactamase inhibitors potentiate the activity of peptide antibiotics daptomycin against methicillin-resistant Staphylococcus aureus and colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 2017 Jan 24;61(2).
  • Liebenstein TL, Schulz LT, Viesselmann C, Bingen E, Musuuza J, Safdar N, Rose WE. Effectiveness of tigecycline compared to a matched treatment cohort in abdominal transplant patients with polymicrobial intra-abdominal infections. Pharmacotherapy. 2017 Fe 37(2):151-158.
  • Gagetti P, Pasteran F, Martinez MP, Fatouraei M, Gu J, Fernandez R, Paz L, Rose WE, Corso A, Rosato AE. Modeling meropenem treatment, alone and in combination with daptomycin, for KPC-producing Klebsiella pneumoniae with unusually low carbapenem MICs. Antimicrob Agents Chemother. 2016 Jul 22;60(8):5047-50.
  • Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson, J, Pogliano J, Sakoulas G, Nizet V, Proctor RA, Rose WE. Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-lactam-daptomycin synergy Antimicrob Agents Chemother 2015 Nov 2;60(1):451-8.
  • Shukla SK, Rose W, Schrodi SJ. Complex host genetic susceptibility to Staphylococcus aureus infections. Trends Microbiol. 2015 Se 23(9):529-36.
  • Barber KE, Smith JR, Ireland CE, Boles BR, Rose WE, Rybak MJ. Evaluation of Ceftaroline Alone and in Combination Against Biofilm-producing Methicillin-resistant Staphylococcus aureus (MRSA) with Reduced Susceptibility to daptomycin and vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4497-503.
  • Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE. Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics. Antimicrob Agents Chemother, 2015 May;59(5):2799-806. 
  • Guerra AD, Cantu DA, Vecchi JT, Rose WE, Hematti P, Kao WJ. Mesenchymal Stromal/Stem Cell and Minocycline-Loaded Hydrogels Inhibit the Growth of Staphylococcus aureus that Evades Immunomodulation of Blood-Derived Leukocytes. AAPS J. 2015 May;17(3):620-30. 
  • Hall Snyder AD, Vidaillac C, Rose W, McRoberts JP, Rybak MJ. Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK/PD model of bacterial biofilm. Infect Dis Ther. 2015; in press.
  • Slane JA, Vivanco JF, Rose WE, Squire MW, Ploeg HL. Mechanical, material, and antimicrobial properties of acrylic bone cement impregnated with silver nanoparticles. Mater Sci Eng C Mater Biol Appl. 2015 Mar;48:188-96.
  • Berti AD, Hutson PR, Schulz PR, Webb A, Rose WE. Compatibility of Cefepime and Vancomycin: Implications for Y-site Co-administration with Prolonged Cefepime Infusion. Am J Health Syst Pharm. 2015 Mar 1;72(5):390-5.
  • Rose WE, Otto DP, Aucamp ME, Miller Z, de Villiers MM. Prevention of Biofilm Formation by Methacrylate-Based Copolymer Films Loaded With Rifampin, Clarithromycin, Doxycycline Alone or in Combination. Pharm Res. Pharm Res. 2015 Ja 32(1):61-73.
  • Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. Antimicrobial Salvage Therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014; 36 (10), 1 October 2014, 1317–1333.
  • Werth BJ, Steed ME, Ireland CE, Tran TT, Nonejuie P, Murray BE, Rose WE, Sakoulas G, Pogliano J, Arias CA, Rybak MJ. Defining Daptomycin Mutant Prevention Exposures in Vancomycin Resistant Enterococcus (VRE) faecium and E. faecalis. Antimicrob Antimicrob Agents Chemother. 2014; 58(9):5253-61.
  • Slane JA, Vivanco JF, Rose WE, Squire MW, Ploeg HL. The influence of low concentrations of a water soluble poragen on the material properties, antibiotic release, and biofilm inhibition of an acrylic bone cement. Mater Sci Eng C Mater Biol Appl. 2014; 42:168-76. 
  • Schulz L, Liebenstein T, Viesselmann C, Sturm E, Rose W. Advancing pharmacy practice through scholarship while engaging pharmacy students during early didactic training. J Am Pharm Assoc (2003). 2014 May-Jun;54(3):212.
  • Rose WE. Meningococcal serogroup B outbreaks and use of 4CMenB vaccine. J Am Pharm Assoc. 2014;54: 198-201.
  • Burke SL, Rose WE. New pharmacological treatments for MRSA infections. Expert Opin Pharmacother. 2014 Mar;15(4): 483-91.
  • Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. Ceftaroline Restores Daptomycin Activity Against Daptomycin Nonsusceptible Vancomycin Resistant Enterococcus faecium. Antimicrob Agents Chemother. 2014 Mar;58(3): 1494-500.  
  • Ng JK, Schulz LT, Rose WE, Fox BC, Andes D, Buhr KA, Fish JT. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother. 2014 Jan;58(1):88-93.
  • Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. β-lactam Antibiotics Targeting PBP1 Selectively Enhance Daptomycin Activity against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Oct;57(10):5005-12.
  • Kullar R, Goff DA, Schulz LT, Fox BC, Rose WE. The EPIC Challenge of Optimizing Antimicrobial Stewardship: the Role of Electronic Medical Records and Technology. Clin Infect Dis 2013 in press. Clin Infect Dis. 2013 Oct;57(7):1005-13. 
  • Rose WE, Berti AD, Hatch JB, Maki DG. Relationship of in vitro Synergy and Treatment Outcome with Daptomycin plus Rifampin in Patients with Invasive Methicillin-resistant Staphylococcus aureus Infections. Antimicrob Agents Chemother. 2013. Jul;57(7):3450-2.
  • Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, Tomasz A, Rybak MJ. Alternative mutational pathways to vancomycin-intermediate resistance in methicillin resistant Staphylococcus aureus. J Infect Dis. 2013 Jul;208(1):67-74.
  • Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid, against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother. 2013 2013 Mar;57(3):1518-20.
  • Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model. Antimicrob Agents Chemother. 2013 Jan;57(1):66-73. 
  • Strydom SJ, Rose WE, Otto DP, Liebenberg W, de Villiers MM. Poly(amidoamine) dendrimer-mediated synthesis and stabilization of silver sulfonamide nanoparticles with increased antibacterial activity. Nanomedicine 2013 Jan;9(1):85-93.
  • Belley A, Arhin FF, Sarmiento I, Deng H, Rose WE, Moeck G. Pharmacodynamics of a simulated single dose of 1200 mg oritavancin in an in vitro pharmacokinetic / pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2013 Jan;57(1):205-11.